Karande Mahesh 4
4 · Omega Therapeutics, Inc. · Filed Feb 9, 2024
Insider Transaction Report
Form 4
Karande Mahesh
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2024-02-07+209,551→ 209,551 totalExercise: $3.59Exp: 2034-02-06→ Common Stock (209,551 underlying) - Award
Stock Option (Right to Buy)
2024-02-07+314,326→ 314,326 totalExercise: $3.59Exp: 2034-02-06→ Common Stock (314,326 underlying)
Footnotes (2)
- [F1]The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter, such that the option will become fully vested and exercisable on February 7, 2028, subject to acceleration on the one-year anniversary of the consummation of a business development deal by the Issuer with terms that satisfy its corporate goals for business development collaborations and subject to the Reporting Person's continued service to the Issuer through each such vesting date.